Stockreport

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin [Yahoo! Finance]

Palvella Therapeutics, Inc.  (PVLA) 
PDF from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved therapies Patent protection extends into 2038 [Read more]